Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
- None.
- None.
Insights
The appointment of Dr. Marc Chamberlain as Chief Medical Officer of Starlight Therapeutics signifies a strategic move to strengthen the company's clinical operations, particularly in the challenging field of neuro-oncology. Dr. Chamberlain's extensive background in both clinical practice and therapeutic development, particularly within the realm of central nervous system and brain cancers, suggests a focused approach to advancing the company's pipeline of therapies. The emphasis on AI-enabled drug development, utilizing Lantern Pharma's RADR® platform, underscores a commitment to innovation and efficiency in addressing unmet medical needs.
The development of STAR-001, a central nervous system penetrant acylfulvene, for the treatment of brain tumors, represents a significant advancement in precision therapeutics. The preclinical success of this compound, coupled with the planned clinical trials for glioblastoma, indicates potential for addressing the high mortality associated with such cancers. The use of AI in drug development could potentially shorten the timeline for clinical trials and reduce costs, which is critical in a field where patients have limited therapeutic options.
Overall, the integration of Dr. Chamberlain's expertise with Lantern's technological capabilities could accelerate the development of novel treatments, potentially leading to improved outcomes for patients with CNS and brain cancers. This could, in turn, impact the company's valuation and attractiveness to investors, as success in this area would represent a significant scientific and commercial breakthrough.
Dr. Chamberlain's leadership in Starlight Therapeutics' clinical operations is poised to have a substantial impact on the development of therapies for various aggressive and fatal brain cancers. His experience with neuro-oncology programs at NCI designated cancer centers provides him with a deep understanding of the clinical challenges and unmet needs in treating glioblastoma, high-grade gliomas and pediatric brain tumors such as ATRT and DIPG. His appointment is likely to bring a patient-centric approach to clinical trial design, potentially improving the translatability of preclinical findings to clinical success.
The focus on glioblastoma, a notoriously difficult-to-treat brain cancer with a poor prognosis, is particularly noteworthy. Current standard-of-care treatments offer limited efficacy and the development of STAR-001 as a novel therapeutic agent could represent a significant advancement. The compound's ability to penetrate the CNS and target brain tumors at a molecular level could provide new hope for patients who have exhausted other treatment options.
Dr. Chamberlain's expertise may also facilitate collaborations with academic and clinical institutions, fostering a multidisciplinary approach that is often essential in the field of neuro-oncology. The potential for developing new treatments under his guidance could have a profound impact on patient care and the future direction of brain cancer therapy.
The strategic hiring of Dr. Chamberlain by Starlight Therapeutics could signal to the market a heightened commitment to advancing its neuro-oncology pipeline. The company's focus on AI-enabled drug development and the progression of STAR-001 into clinical trials for glioblastoma may attract investor interest due to the high unmet need and the large market potential for effective brain cancer treatments.
Investors often look for companies that are not only innovating but also strategically positioning themselves to tackle difficult-to-treat diseases. The use of AI and machine learning in drug development is a growing trend that can potentially lead to more personalized medicine and improved success rates in clinical trials. This approach could differentiate Lantern Pharma and Starlight Therapeutics in a competitive oncology market.
From a financial perspective, successful clinical outcomes for STAR-001 could lead to significant revenue opportunities for Lantern Pharma and its subsidiary. However, investors should also be aware of the inherent risks associated with drug development, particularly in an area as complex as brain cancer. The long-term success of the company will depend on its ability to navigate the regulatory landscape, achieve clinical milestones and ultimately deliver effective treatments to the market.
Starlight and Lantern Logos (Joint)
Dr. Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric neurology and neuro-oncology. His experience before joining Starlight has included serving as the co-director of the neuro-oncology programs at 4 NCI designated cancer centers— Moores Cancer Center at UC San Diego, Norris Cancer Center at USC, Moffit Cancer Center at the University of
“Starlight Therapeutics and Lantern Pharma are poised to transform oncology with AI-enabled drug development aimed at providing advanced precision therapeutics for cancers in areas of severely unmet need, such as multiple types of pediatric and adult brain cancers, for which there is currently no cure,” said Panna Sharma, CEO and President of Lantern Pharma. “Dr. Chamberlain’s insight and expertise in neuro-oncology and therapeutic development will be invaluable to the further development of treatments already in the pipeline, and the discovery and development of new future treatments that are so desperately needed by cancer patients, especially in neuro-oncology.”
Dr. Chamberlain earned his medical degree at the
“Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001” for CNS indications), to target tumors in the brain. We are now preparing for two recurrent glioblastoma studies as part of a larger planned expansion study to assess STAR-001 in subjects who have failed standard-of-care temozolomide and involved field radiotherapy. The development of STAR-001 for use in brain tumors has utilized Lantern’s proprietary RADR® platform of in silico modeling as well as extensive preclinical experimentation in multiple in-vitro and in-vivo models,” said Dr. Chamberlain. “I’m looking forward to working alongside the talented researchers and experts at Lantern and its collaborators at Starlight who have already done so much to advance these treatments. I look forward to working together with our collaborators and clinicians to bring these and many more innovative neuro-oncology treatments to the patients who need them.”
Formed in Q1 of 2023, Starlight Therapeutics is leveraging RADR®— Lantern Pharma’s proprietary artificial intelligence and machine learning platform focused on transforming the cost, pace and timeline of oncology drug discovery and development— to research, develop and clinically advance therapeutics for CNS and brain cancers.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) RADR® platform leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately
Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of STAR-001 and our other product candidates; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of STAR-001 and our other drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and biomarker data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iii) the risk that success in early phases of pre-clinical and clinicals trials does not ensure later clinical trials will be successful; (iv) our future ability to fund the clinical trials and further development of STAR-001 and other product candidates and the availability of capital if and when needed, (v) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 20, 2023. You may access our Annual Report on Form 10-K for the year ended December 31, 2022 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117468908/en/
Investor Relations
ir@lanternpharma.com
Source: Lantern Pharma
FAQ
Who has joined Starlight Therapeutics as its Chief Medical Officer?
What is the ticker symbol for Lantern Pharma?
What is the focus of Starlight Therapeutics' clinical development?
What is the name of the CNS penetrant wholly synthetic acylfulvene developed by Starlight Therapeutics?
What is RADR®?
